-- Continuing to advance lead asset LFB190, a BET inhibitor, targeting EP300 loss--of--function cancers; expect to initiate Phase 1b/2a clinical trial in solid tumors in mid-2026 -- SOUTH SAN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results